Long-Acting Insulins Approved by FDA

by U.S. Medicine

October 11, 2015

PLAINSBORO, NJ – Physicians treating diabetes patients have new weapons in their arsenal.

The Food and Drug Administration recently approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve glucose control in adults with diabetes mellitus.

Both drugs are manufactured by Novo Nordisk in Plainsboro, NJ.

“Long-acting insulins play an essential role in the treatment of patients with type 1 diabetes and in patients with type 2 diabetes with advanced disease,” said Jean-Marc Guettier, MD, director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “The FDA remains committed to support the development of innovative therapies for the treatment of diabetes.”

Tresiba is a long-acting insulin analog indicated to improve glycemic control in adults with type 1 and 2 diabetes mellitus. Dosing of Tresiba, which is administered subcutaneously once daily at any time of day, should be individualized based on the patient’s needs, according to the FDA.

Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog. It is indicated to improve glycemic control in adults with diabetes mellitus. 

The FDA warned that Tresiba and Ryzodeg should not be used in those who have diabetic ketoacidosis. It also cautioned that the drugs can cause potentially life-threatening hypoglycemia, adding, “Patients should be monitored more closely with changes to insulin dosage, co-administration of other glucose-lowering medications, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness.”


Related Articles

Preventing, Treating Diabetic Foot Ulcers Are Complex Challenges at VA

Some of the risks of diabetic foot ulcers (DFUs) are well-known, including infection and, in the most severe cases, amputation.

Evidence of CV Benefit Influences Diabetes Treatment Recommendations

In a significant change, the American Diabetes Association’s 2018 guidelines advocate use of a glucose-lowering agent with proven cardiovascular benefit or mortality reduction in patients with Type 2 diabetes mellitus (T2DM) and co-morbid cardiovascular disease.


U.S. Medicine Recommends


More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

FDA Approves Option for Schizophrenia, Bipolar Treatment

WASHINGTON — In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC). The rate of new drug approvals has outpaced the ability of... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

WASHINGTON — In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC). The rate of new drug approvals has outpaced the ability of... View Article

FDA News

FDA Approves Tecfidera for Treatment of Relapsing MS

WASHINGTON — In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC). The rate of new drug approvals has outpaced the ability of... View Article

FDA News

Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies

WASHINGTON — In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC). The rate of new drug approvals has outpaced the ability of... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up